bpc 157 fda approval status pipeline clinical trials Peptides, explained: Answers to your top questions TB-500 FDA Approval Status 2026

The study found no significant differences in systemic side effects between routes, but noted that injection site reactions were the leading cause of treatment discontinuation (3% of injectable users versus 1% of oral users discontinuing due to GI upset)

These products are labeled for research use only

Reduced Inflammation

Subject to the satisfactory completion of these testing milestones, the Company intends to progress the product closer to commercial release as part of The Precision Peptide Company's product portfolio

More studies continue to explore their potential to accelerate tissue repair and regeneration